Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Overview
Date Founded

1993

Headquarters

Acme Plaza,Andheri-Kurla Road,Andheri East,Mumbai, Maharashtra 400059

Type of Company

Public

Employees (Worldwide)

32K

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Contact Data
Trying to get in touch with decision makers at Sun Pharmaceutical Industries Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Executive Officer-India Subcontinent

Senior General Manager, International Marketing

Chief Compliance Officer

Head, Business & Emerging Markets

Head-Media Relations

Senior Vice President & Head-Human Resources

Head, Russia

Senior Vice President-Business Development

Vice President & Head Ophthalmic Business

Board of Directors

Chairman at Gesher Theater

Founder at Sun Pharmaceutical Industries Ltd.

Executive Chairman at Samvardhana Motherson International Ltd.

Managing Director at Housing Development Finance Corp. Ltd.

Founder at Hitech Corp. Ltd.

Professional at Suraksha Realty Ltd.

Head, Business & Emerging Markets at Sun Pharmaceutical Industries Ltd.

Director General at All India Management Association

Group Managing Director at Reliance Anil Dhirubhai Ambani Group Ltd.

Former Managing Director at Tamil Nadu Dadha Pharmaceuticals Ltd.

Paths to Sun Pharmaceutical Industries Ltd.
Potential Connections via
Relationship Science
You
Sun Pharmaceutical Industries Ltd.
Owners & Shareholders
Details Hidden

LIC invests in capital and debt markets, including government securities. Their equity investments consist of Indian shares in all sectors, with an emphasis on the infrastructure, industrial and social sectors. They also invest in Central and State Government bonds, as well as in debentures and term loans. LIC follows a bottom-up investment process which is based on fundamental research combining in-house and outsourced analysis. They seek to invest in high-growth equity, favoring leaders within each sector. They target companies with strong fundamentals and also invest in mid-cap stocks with high liquidity.

Details Hidden

ICICI Prudential AM follows a bottom-up investment approach and base stock selection on the fundamental assessment of companies. The firm seeks to identify investment opportunities by using quantitative models to screen the market. Their research process includes a company visitation program.

Details Hidden

ABSLAMC is a long-term, fundamental research-based investor which manages portfolios invested in equity, fixed-income and money-market instruments across regions and sectors. These assets are available via a wide range of financial vehicles including diversified or sector specific equity funds, fund of funds, hybrid and monthly income funds, debt and treasury products and offshore funds. These funds can be actively or passively managed. The firm's equity fund invests in stocks/equity shares of companies of different market capitalization. These funds can be actively or passively managed. Their debt mutual fund invests in a mix of debt investments such as treasury bills, government securities (G-Secs), corporate bonds and other money market instruments of varying maturities that seek to provide investors capital preservation and regular income. ABSLAMC's hybrid fund invests in a mix of growth oriented equity, capital preserving debt and other assets related instruments, which can vary proportionally over time or remain fixed.

Recent Transactions
Details Hidden

Sun Pharmaceutical Industries Ltd. purchases Pola Pharma, Inc. from Pola Orbis Holdings Inc.

Details Hidden

Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Europe BV purchase Ranbaxy (Malaysia) Sdn. Bhd.

Details Hidden

Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Europe BV purchase Ranbaxy (Malaysia) Sdn. Bhd.

Transaction Advisors
Legal Advisor

Advised onSun Pharmaceutical Industries Ltd. purchases Ranbaxy Laboratories Limited

Legal Advisor

Advised onSun Pharmaceutical Industries Ltd. purchases DUSA Pharmaceuticals, Inc.

Investment Advisor

Advised onSun Pharmaceutical Industries Ltd. purchases Taro Pharmaceutical Industries Ltd. from Templeton Asset Management Ltd. (Hong Kong)

Corporate Officer

Advised onSun Pharmaceutical Industries Ltd., Alkaloida Chemical Co. Exclusive Group Ltd. purchase Taro Pharmaceutical Industries Ltd.

Legal Advisor

Advised onSun Pharmaceutical Industries Ltd., Alkaloida Chemical Co. Exclusive Group Ltd. purchase Taro Pharmaceutical Industries Ltd.

Investment Advisor

Advised onSun Pharmaceutical Industries Ltd., Alkaloida Chemical Co. Exclusive Group Ltd. purchase Taro Pharmaceutical Industries Ltd.

Advisors & Consultants
Legal Advisor

Partner at Winston & Strawn LLP

Legal Advisor

Partner at Winston & Strawn LLP

Clients

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

We are a pharma research and drug discovery company. We were formed in 2007, when India’s leading speciality pharma company, Sun Pharmaceutical Industries Ltd, separated out its active projects in drug discovery and innovation into a new company. This was done in order to bring in the right focus and opportunity for growth for these projects that address international markets. A team of scientists has been working since the year 2000 on these projects which are now at different stages of preclinical and clinical development. Sun Pharma, the parent company, continues to invest independently in generic research, both for process development for API and formulation development for dosage forms

Key Stats and Financials As of 2019
Market Capitalization
$1.05T
Total Enterprise Value
$1.18T
Earnings Per Share
$11.11
Revenue
$291B
Net Profit
$26.7B
EBITDA
$66.8B
EBITDAMargin
22.97%
Total Debt
$105B
Total Equity
$447B
Enterprise Value Sales
4.05x
Enterprise Value EBITDAOperating
17.62x
TEVNet Income
44.12x
Debt TEV
0.09x
Three Year Compounded Annual Growth Rate Of Revenue
1.56%
Five Year Compounded Annual Growth Rate Of Revenue
12.68%
Investments
Details Hidden

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Suppliers
Ess Dee Aluminium Ltd. Paper Products | Mumbai, MA

Ess Dee Aluminium Ltd. is a holding company, which engages in the manufacture of packaging materials for pharmaceutical, food, and fast-moving consumer goods industries. It specializes in cold form blister and child-resistant-blister packaging. The company was founded in 1991 and is headquartered in Mumbai, India.

Cipher Pharmaceuticals, Inc. Medical Support Services | Mississauga, ON

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. It acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products. Its products include dermatology, hospital acute care, and out-licensed products. The company was founded in 2000 and is headquartered in Oakville, Canada.

EPIRUS Biopharmaceuticals, Inc. Biotechnology | Boston, MA

EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on building a biosimilar business. It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference product. The company was founded on November 26, 2008 and is headquartered in Boston, MA.

Competitors
Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Torrent Pharmaceuticals Ltd. Pharmaceuticals - Ahmedabad, GU

The Torrent group integrates people, processes and potential towards the betterment of mankind. It all began with the toil of one enterprising individual, Shri. U N Mehta, when he ventured on his own to create history in the Indian pharmaceutical industry by implementing successfully the concept of niche marketing. His journey, characterised by ups and downs, reached a milestone in 1970, with the launch of Trinicalm Plus, an effective tranquilizer in the niche segment, central nervous system (CNS). The foundations for Torrent were laid when 'Trinity Laboratories' began operations under the able guidance of Shri Mehta whose efforts are worthy of emulation. 'Trinity' was renamed 'Torrent' and with this not only did the company get a new name, it also focused on establishing its own manufacturing facilities in the early 80s. Torrent augmented its efforts with the expansion of its manufacturing capacity, emphasis on marketing and creating business opportunities through focus on exports. Torrent Pharmaceuticals Limited recorded a quantum leap in the year 1994. It has also been rated India's ninth best company among capital intensive companies in terms of ROCE in a study by ETIG-BCG in 2001. In recognition of the consistent performance Torrent Pharmaceuticals Limited has been receiving accolades from various quarters, such as the President's award for highest pharmaceuticals exports of Rs. 1570 million in 1991-92. The Company that had a humble beginning has now grown to become one of the leading players in pharmaceuticals. It has ambitious plans for the years ahead. The emphasis is on Post-2005 opportunities with greater focus on the international market, in particular the lucrative North American market

Cipla Ltd. Pharmaceuticals - Mumbai, MA

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Awards & Honors
2015
Forbes Asia - Asia's Fab 50 List
Sponsored by Forbes Magazine
Rank #65
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
2014
Forbes Asia - Asia's Fab 50 List
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sun Pharmaceutical Industries Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sun Pharmaceutical Industries Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Sun Pharmaceutical Industries Ltd..